

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM588145

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Green Hill Healthcare Communications, LLC		07/16/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	The Lynx Group, LLC		
Street Address:	1249 South River Road, Suite 202A		
City:	Cranbury		
State/Country:	NEW JERSEY		
Postal Code:	08512		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	5357418	CONQUER	
Registration Number:	5084500	CONSIDERATIONS IN LYMPHOMA	
Registration Number:	5098044	CONSIDERATIONS IN MULTIPLE MYELOMA	
Registration Number:	4749801	IMMUNOTHERAPY IN ONCOLOGY	
Registration Number:	4017380	THE ONCOLOGY NURSE-APN/PA	
Registration Number:	4014148	THE ONCOLOGY NURSE-APN/PA	
Registration Number:	4017379	THE ONCOLOGY NURSE-APN/PA	
Registration Number:	4017381	THE ONCOLOGY NURSE-APN/PA	
Registration Number:	3555609	THE ONCOLOGY PHARMACIST	
Registration Number:	3555608	THE ONCOLOGY PHARMACIST	
Serial Number:	85263844	PERSONALIZED MEDICINE IN HEMATOLOGY/ONCO	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	langanj@gtlaw.com		
Correspondent Name:	Brian L. Petrequin, Esq.		
Address Line 1:	500 Campus Drive, Suite 400		
Address Line 4:	Florham Park, NEW JERSEY 07932		

CH \$290.00 5357418

ATTORNEY DOCKET NUMBER:	193018010100
NAME OF SUBMITTER:	Brian L. Petrequin, Esq.
SIGNATURE:	/Brian L. Petrequin, Esq./
DATE SIGNED:	07/23/2020

Total Attachments: 10

source=Tradement Agreement - Green Hill - Signed#page1.tif
source=Tradement Agreement - Green Hill - Signed#page2.tif
source=Tradement Agreement - Green Hill - Signed#page3.tif
source=Tradement Agreement - Green Hill - Signed#page4.tif
source=Tradement Agreement - Green Hill - Signed#page5.tif
source=Tradement Agreement - Green Hill - Signed#page6.tif
source=Tradement Agreement - Green Hill - Signed#page7.tif
source=Tradement Agreement - Green Hill - Signed#page8.tif
source=Tradement Agreement - Green Hill - Signed#page9.tif
source=Tradement Agreement - Green Hill - Signed#page10.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT (“**Trademark Assignment**”), dated as of July ~~16~~¹⁴ 2020, is made by GREEN HILL HEALTHCARE COMMUNICATIONS, LLC, a Delaware limited liability company located at 1249 South River Road, Suite 202, Cranbury, New Jersey 08512 (“**Assignor**”), in favor of THE LYNX GROUP, LLC, a Delaware limited liability company located at 1249 South River Road, Suite 202A, Cranbury, New Jersey 08512 (“**Assignee**”).

WHEREAS, Assignor and Assignee are affiliates and believe it is in the best interest of each of such parties to reorganize and restructure their operations and assets such that Assignor has conveyed, transferred or assigned, or will, pursuant to this Trademark Assignment, convey, transfer, and assign to Assignee, among other assets, certain intellectual property of Assignor, and has agreed to execute and deliver this Trademark Assignment, to assign the Assigned Trademarks for recording with the United States Patent and Trademark Office and corresponding entities or agencies in any applicable jurisdictions;

NOW THEREFORE, the parties agree as follows:

1. Assignment. In consideration of the sum of Ten Dollars (\$10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby irrevocably conveys, transfers, and assigns to Assignee, and Assignee hereby accepts, all of Assignor’s right, title, and interest in and to the following:

(a) the trademark registrations, trademark applications and common law marks set forth on Schedule 1 hereto and all issuances, extensions, and renewals thereof (the “**Assigned Trademarks**”), together with the goodwill of the business connected with the use of, and symbolized by, the Assigned Trademarks; provided that, with respect to the United States intent-to-use trademark applications set forth on Schedule 1 hereto, the transfer of such applications accompanies, the transfer of Assignor’s business, or that portion of the business to which the trademark pertains, and that business is ongoing and existing;

(b) all rights of any kind whatsoever of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(c) any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(d) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation and Further Actions. Assignor hereby authorizes the Commissioner for Trademarks in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this Trademark Assignment upon request by Assignee. Following the date hereof, upon Assignee's reasonable request, and at Assignee's sole cost and expense, Assignor shall take such steps and actions, and provide such cooperation and assistance to Assignee and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect, evidence, or perfect the assignment of the Assigned Trademarks to Assignee, or any assignee or successor thereto.

3. Counterparts. This Trademark Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same agreement. A signed copy of this Trademark Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Trademark Assignment.


4. Successors and Assigns. This Trademark Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

5. Governing Law. This Trademark Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this Trademark Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New Jersey without giving effect to any choice or conflict of law provision or rule (whether of the State of New Jersey or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Assignor has duly executed and delivered this Trademark Assignment as of the date first written above.


GREEN HILL HEALTHCARE
COMMUNICATIONS, LLC

By: 
Name: Brian F. Tyburski
Title: President and CEO
Notice Address: 241 Forsgate Drive, Suite 205B
Monroe Township, NJ 08831

ACKNOWLEDGMENT

STATE OF NEW JERSEY)
)SS.
COUNTY OF MIDDLESEX)


On the 16th day of July 2020, before me personally appeared Brian F. Tyburski, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as the President and Chief Executive Officer of Green Hill Healthcare Communications, LLC, a Delaware limited liability company ("Assignor"), and acknowledged the instrument to be the free act and deed of Assignor for the uses and purposes mentioned in the instrument.


Notary Public
Printed Name: LISA CIRILLO

My Commission Expires: 7/19/2022

AGREED TO AND ACCEPTED:


Lisa Cirillo
Notary Public
State of New Jersey
Expires 7/19/2022
Comm. Number 2362183

THE LYNX GROUP, LLC
By: 
Name: Brian F. Tyburski
Title: President and CEO
Notice Address: 1249 South River Rd.,
Suite 202A
Cranbury, New Jersey 08512

ACKNOWLEDGMENT

STATE OF NEW JERSEY)
)SS.
COUNTY OF MIDDLESEX)

On the 16th day of July 2020, before me personally appeared Brian F. Tyburski, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as the President and Chief Executive Officer of The Lynx Group, LLC, a Delaware limited liability company ("Assignee"), and acknowledged the instrument to be the free act and deed of Assignee for the uses and purposes mentioned in the instrument.


Notary Public
Printed Name: LISA CIRILLO

My Commission Expires: 7/19/2022

Lisa Cirillo
Notary Public
State of New Jersey
Expires 7/19/2022
Comm. Number 2362183

Legend: This Trademark Assignment may, but is not required by the parties to, be recorded with the United States Patent and Trademark Office with respect to the Marks indicated with an asterisk "*".

SCHEDULE 1

Assigned Trademarks

1. Active Trademark Registrations

Mark	Jurisdiction	Registration Number	Registration Date
CONQUER	USA	5357418	19-Dec-2017
CONSIDERATIONS IN LYMPHOMA	USA	5084500	22-Nov-2016
CONSIDERATIONS IN MULTIPLE MYELOMA	USA	5098044	13-Dec-2016
IMMUNOTHERAPY IN ONCOLOGY	USA	4749801	02-Jun-2015
THE ONCOLOGY NURSE-APN/PA	USA	4017380	23-Aug-2011
THE ONCOLOGY NURSE-APN/PA	USA	4014148	16-Aug-2011
THE ONCOLOGY NURSE-APN/PA	USA	4017379	23-Aug-2011
THE ONCOLOGY NURSE-APN/PA	USA	4017381	23-Aug-2011
THE ONCOLOGY PHARMACIST	USA	3555609	30-Dec-2008
THE ONCOLOGY PHARMACIST	USA	3555608	30-Dec-2008

2. Pending Trademark Applications





Mark	Jurisdiction	Application Serial Number/Reg. Number	Filing/Reg. Date
CLINICAL ONCOLOGY PHARMACY	USA	77295684*	03-Oct-2007
CLINICAL ONCOLOGY PHARMACY	USA	77738718*	16-May-2009
CLINICAL ONCOLOGY PHARMACY NEWS	USA	77295689*	03-Oct-2007
CLINICAL ONCOLOGY PHARMACY NEWS	USA	77738719*	16-May-2009
JOURNAL OF PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263888*	10-Mar-2011
JOURNAL OF PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263884*	10-Mar-2011
JOURNAL OF PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263856*	10-Mar-2011
JOURNAL OF PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263848*	10-Mar-2011
ONCOLOGY PHARMACY NEWS	USA	77738721*	16-May-2009
ONCOLOGY PHARMACY NEWS	USA	77295691*	03-Oct-2007
ONCOLOGY PHARMACY TIMES	USA	77295695*	03-Oct-2007

PERSONALIZED CANCER CARE	USA	85263897*	10-Mar-2011
PERSONALIZED CANCER CARE	USA	85263871*	10-Mar-2011
PERSONALIZED CANCER CARE	USA	85263877*	10-Mar-2011
PERSONALIZED CANCER CARE	USA	85263835*	10-Mar-2011
PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263844	10-Mar-2011
PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263881*	10-Mar-2011
PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263862*	10-Mar-2011
PERSONALIZED MEDICINE IN HEMATOLOGY/ONCOLOGY	USA	85263894*	10-Mar-2011
PERSONALIZED MEDICINE IN IMMUNOLOGY	USA	85473286*	15-Nov-2011
PERSONALIZED MEDICINE IN RHEUMATOLOGY	USA	85473317*	15-Nov-2011
TARGETED THERAPIES IN HEMATOLOGY/ONCOLOGY	USA	85473323*	15-Nov-2011
TARGETED THERAPIES IN ONCOLOGY	USA	85473337*	15-Nov-2011

3. Common Law Marks

<u>Mark</u>	<u>Jurisdiction</u>	<u>Application Serial Number/Reg. Number</u>	<u>Filing/Reg. Date</u>
IMMUNOTHERAPY IN ONCOLOGY	USA	87107330*	18-July-2016 (Abandoned: 08/22/17)
IMMUNO-ONCOLOGY NEWS	USA	87107091*	18-July-2016 (Abandoned: 08/22/17)
IMMUNOLOGY NEWS	USA	87107061*	18-July-2016 (Abandoned: 08/22/17)
CONQUER	USA	86439143*	29-Oct-2014 (Abandoned: 10/11/16)
CONQUER	USA	86439139*	29-Oct-2014 (Abandoned: 10/11/16)
IMMUNOTHERAPY IN ONCOLOGY	USA	86603015*	20-Apr-2015 (Abandoned: 07/01/16)
IMMUNO-ONCOLOGY NEWS	USA	86602939*	20-Apr-2015 (Abandoned: 07/01/16)
IMMUNOLOGY NEWS	USA	86602921*	20-Apr-2015 (Abandoned: 07/01/16)
CONQUER	USA	86439137*	29-Apr-2014 (Abandoned: 08/17/15)
IMMUNO-ONCOLOGY NEWS	USA	86136260*	05-Dec-2013 (Abandoned: 04/23/15)
IMMUNOLOGY NEWS	USA	86136220*	05-Dec-2013 (Abandoned: 04/23/15)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85418664*	09-Sept-2011 (Cancelled: 03/15/19)

RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85418653*	09-Sept-2011 (Cancelled: 03/15/19)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85418647*	09-Sept-2011 (Cancelled: 03/15/19)
REMS REVIEW	USA	85418638*	09-Sept-2011 (Cancelled: 03/15/19)
PERSONALIZED MEDICINE IN ONCOLOGY	USA	85473354*	15-Sept-2011 (Abandoned: 08/07/18)
REMS REVIEW	USA	85041033*	18-May-2010 (Cancelled: 05/26/17)
REMS REVIEW	USA	85041021*	18-May-2010 (Cancelled: 05/26/17)
PERSONALIZED BREAST CANCER	USA	85538950*	09-Feb-2012 (Abandoned: 08/08/16)
PERSONALIZED BREAST CANCER	USA	85538948*	09-Feb-2012 (Abandoned: 08/08/16)
PERSONALIZED BREAST CANCER	USA	85538947*	09-Feb-2012 (Abandoned: 08/08/16)
PERSONALIZED BREAST CANCER	USA	85538946*	09-Feb-2012 (Abandoned: 08/08/16)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85418660*	09-Sept-2011 (Abandoned: 06/10/13)
REMS REVIEW	USA	85418548*	09-Sept-2011 (Abandoned: 06/30/12)
Leadership Cheatham County	USA	85345898*	14-June-2011 (Abandoned: 09/19/11)

RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85041043*	18-May-2010 (Abandoned: 08/05/11)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85041040*	18-May-2010 (Abandoned: 09/05/11)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85041039*	18-May-2010 (Abandoned: 09/05/11)
RISK EVALUATION & MITIGATION STRATEGIES REVIEW	USA	85041037*	18-May-2010 (Abandoned: 09/05/11)
REMS REVIEW	USA	85041028*	18-May-2010 (Abandoned: 09/02/11)
REMS REVIEW	USA	85041025*	18-May-2010 (Abandoned: 09/02/11)
THE OB/GYN AND INFERTILITY NURSE	USA	77820857*	04-Sept-2009 (Cancelled: 03/03/17)
 The OB/GYN and INFERTILITY Nurse <small>THE OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF OB/GYN AND INFERTILITY NURSES</small>	USA	77821998*	08-Sept-2009 (Cancelled: 05/12/17)
 The OB/GYN and INFERTILITY Nurse <small>THE OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF OB/GYN AND INFERTILITY NURSES</small>	USA	77821988*	08-Sept-2009 (Cancelled: 05/12/17)
 The OB/GYN and INFERTILITY Nurse <small>THE OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF OB/GYN AND INFERTILITY NURSES</small>	USA	77821981*	08-Sept-2009 (Cancelled: 05/12/17)
THE OB/GYN AND INFERTILITY NURSE	USA	77820850*	04-Sept-2009 (Cancelled: 02/17/17)
THE OB/GYN AND INFERTILITY NURSE	USA	77820843*	04-Sept-2009 (Cancelled: 02/17/17)
 The OB/GYN and INFERTILITY Nurse <small>THE OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF OB/GYN AND INFERTILITY NURSES</small>	USA	77821994*	08-Sept-2009 (Cancelled: 02/10/17)

THE OB/GYN NURSE	USA	77911362*	13-Jan-2010 (Cancelled: 01/06/17)
THE OB/GYN NURSE	USA	77911351*	13-Jan-2010 (Cancelled: 01/06/17)
THE INFERTILITY NURSE	USA	77911339*	13-Jan-2010 (Cancelled: 01/06/17)
THE INFERTILITY NURSE	USA	77911327*	13-Jan-2010 (Cancelled: 01/06/17)
JOURNAL OF MULTIDISCIPLINARY CANCER CARE	USA	77757411*	11-June-2009 (Cancelled: 05/13/16)
JOURNAL OF MULTIDISCIPLINARY CANCER CARE	USA	77757392*	11-June-2009 (Cancelled: 05/13/16)
JOURNAL OF MULTIDISCIPLINARY CANCER CARE	USA	77739200*	18-May-2009 (Cancelled: 05/13/16)
JOURNAL OF MULTIDISCIPLINARY CANCER CARE	USA	77739182*	18-May-2009 (Cancelled: 05/13/16)
The Oncology Nurse	USA	77561035*	03-Sept-2008 (Cancelled: 12/25/15)
The Oncology Nurse	USA	77562743*	04-Sept-2008 (Cancelled: 12/18/15)
THE OB/GYN AND INFERTILITY NURSE	USA	77820853*	04-Sept-2009 (Cancelled: 01/07/11)
ONCOLOGY PHARMACY TIMES	USA	77738722*	01-Sept-2009 (Cancelled: 01/25/12)